SINGAPORE, May 28, 2026
Gene Solutions announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to SPOT-MAS 10, the company’s multi-cancer early detection blood test designed to identify cancer-associated signals using a multi-omics and AI-driven platform. The designation marks a major regulatory milestone for the biotechnology company as it advances commercialization plans for the United States and global expansion of its cancer screening technology.
FDA Recognition Boosts Multi-Cancer Screening Innovation
The FDA granted the designation to SPOT-MAS 10 based on its potential to provide more effective diagnosis of life-threatening cancers compared with currently available screening options. The designation does not represent FDA approval or clearance but enables prioritized interactions with the agency during the regulatory review process.
SPOT-MAS 10 is a multi-omics liquid biopsy blood test designed for asymptomatic adults aged 40 years and older. The test analyzes circulating cell-free DNA methylation and fragmentomic signals using a machine-learning-based algorithm to detect cancer-associated abnormalities from a single blood sample.
The platform is designed to assist in the detection of 10 cancer types, including five common cancers — breast, lung, liver, colorectal, and gastric cancers — as well as five aggressive cancers with limited screening options, including ovarian, pancreatic, esophageal, endometrial, and head & neck cancers.
Advertisement
According to Dr. Nguyen Hoai Nghia, CEO and Co-founder of Gene Solutions, the FDA designation validates the company’s strategy of combining genomics, epigenetics, and artificial intelligence to improve early cancer detection. He described the recognition as a defining milestone that strengthens the company’s mission to make precision oncology technologies more accessible worldwide.
SPOT-MAS Demonstrates Strong Clinical and Real-World Performance
Gene Solutions highlighted that SPOT-MAS became the first multi-cancer early detection blood test in Asia to complete a large prospective cohort validation study. Results from the K-DETEK study, published in BMC Medicine, evaluated more than 9,000 asymptomatic participants and demonstrated high specificity along with strong cancer signal detection performance across multiple tumor types.
The company also revealed that SPOT-MAS has already been used in more than 100,000 individuals in real-world clinical settings, providing additional evidence supporting the platform’s scalability and consistency outside controlled clinical trials. Updated real-world findings were presented at ESMO Asia 2025, with further data expected to be showcased at ASCO Breakthrough 2026 in Singapore.
The technology combines genetics, epigenetics, fragmentomics, and AI-powered analysis to improve detection sensitivity while maintaining specificity necessary for responsible population-level cancer screening. Researchers involved in the project stated that relying on multiple biological signals rather than a single biomarker allows deeper analysis of circulating tumor DNA patterns from blood samples.
U.S. Expansion and Commercialization Strategy Accelerates
The FDA Breakthrough Device Designation strengthens Gene Solutions’ regulatory and commercialization strategy as the company pushes toward U.S. market entry. Management stated that the designation creates a more structured pathway for engagement with the FDA while supporting ongoing validation and laboratory expansion efforts in the United States.
SPOT-MAS is currently available through selected hospitals and clinics across Asia, while Gene Solutions continues expanding internationally into markets including Brazil, Turkey, and the Middle East. The company is targeting U.S. launch readiness by late 2026, supported by ongoing clinical validation and infrastructure development.
Gene Solutions emphasized that SPOT-MAS 10 is intended to complement, not replace, guideline-recommended cancer screening methods. Patients receiving positive test results would still require physician-directed diagnostic confirmation based on predicted tissue of origin.
The latest FDA designation places Gene Solutions among a select group of companies developing next-generation multi-cancer early detection (MCED) technologies, one of the fastest-growing areas in precision oncology and liquid biopsy diagnostics. Industry interest in AI-powered cancer screening platforms continues to rise as healthcare systems seek earlier detection methods capable of improving survival outcomes and reducing late-stage cancer diagnoses.
Source: Gene Solutions press release
